396 related articles for article (PubMed ID: 25943176)
1. Effect of mavoglurant (AFQ056), a selective mGluR5 antagonist, on the pharmacokinetics of a combined oral contraceptive containing ethinyl estradiol and levonorgestrel in healthy women.
Sivasubramanian R; Chakraborty A; Rouzade-Dominguez ML; Neelakantham S; Jakab A; Mensinga T; Legangneux E; Woessner R; Ufer M
Int J Clin Pharmacol Ther; 2015 Jul; 53(7):550-6. PubMed ID: 25943176
[TBL] [Abstract][Full Text] [Related]
2. Effect of empagliflozin on the steady-state pharmacokinetics of ethinylestradiol and levonorgestrel in healthy female volunteers.
Macha S; Mattheus M; Pinnetti S; Woerle HJ; Broedl UC
Clin Drug Investig; 2013 May; 33(5):351-7. PubMed ID: 23512637
[TBL] [Abstract][Full Text] [Related]
3. A comparison of the pharmacokinetic profile of an ascending-dose, extended-regimen combined oral contraceptive to those of other extended regimens.
Darwish M; Bond M; Ricciotti N; Hsieh J; Fiedler-Kelly J; Grasela T
Reprod Sci; 2014 Nov; 21(11):1401-10. PubMed ID: 24647707
[TBL] [Abstract][Full Text] [Related]
4. Atogepant Has No Clinically Relevant Effects on the Pharmacokinetics of an Ethinyl Estradiol/Levonorgestrel Oral Contraceptive in Healthy Female Participants.
Ankrom W; Xu J; Vallee MH; Dockendorf MF; Armas D; Boinpally R; Min KC
J Clin Pharmacol; 2020 Sep; 60(9):1157-1165. PubMed ID: 32297990
[TBL] [Abstract][Full Text] [Related]
5. Steady-state pharmacokinetics of an extended-regimen oral contraceptive with continuous estrogen.
DiLiberti CE; O'Leary CM; Hendy CH; Waters DH; Margolis MB
Contraception; 2011 Jan; 83(1):55-61. PubMed ID: 21134504
[TBL] [Abstract][Full Text] [Related]
6. Effect of multiple oral doses of linagliptin on the steady-state pharmacokinetics of a combination oral contraceptive in healthy female adults: an open-label, two-period, fixed-sequence, multiple-dose study.
Friedrich C; Port A; Ring A; Graefe-Mody U; Giessmann T; Iovino M; Woerle HJ
Clin Drug Investig; 2011; 31(9):643-53. PubMed ID: 21714581
[TBL] [Abstract][Full Text] [Related]
7. Pharmacodynamic and pharmacokinetic evaluation of coadministration of lacosamide and an oral contraceptive (levonorgestrel plus ethinylestradiol) in healthy female volunteers.
Cawello W; Rosenkranz B; Schmid B; Wierich W
Epilepsia; 2013 Mar; 54(3):530-6. PubMed ID: 23360419
[TBL] [Abstract][Full Text] [Related]
8. Effect of the hepatitis C virus protease inhibitor faldaprevir on the pharmacokinetics of an oral contraceptive containing ethinylestradiol and levonorgestrel in healthy female volunteers.
Sabo JP; Lang B; Elgadi M; Huang F
Antimicrob Agents Chemother; 2015 Jan; 59(1):514-9. PubMed ID: 25385099
[TBL] [Abstract][Full Text] [Related]
9. Pharmacokinetics of levonorgestrel and ethinylestradiol in 14 women during three months of treatment with a tri-step combination oral contraceptive: serum protein binding of levonorgestrel and influence of treatment on free and total testosterone levels in the serum.
Kuhnz W; Staks T; Jütting G
Contraception; 1994 Dec; 50(6):563-79. PubMed ID: 7705098
[TBL] [Abstract][Full Text] [Related]
10. Effect of canagliflozin, a sodium glucose co-transporter 2 inhibitor, on the pharmacokinetics of oral contraceptives, warfarin, and digoxin in healthy participants.
Devineni D; Manitpisitkul P; Vaccaro N; Bernard A; Skee D; Mamidi RN; Tian H; Weiner S; Stieltjes H; Sha S; Rothenberg P
Int J Clin Pharmacol Ther; 2015 Jan; 53(1):41-53. PubMed ID: 25345427
[TBL] [Abstract][Full Text] [Related]
11. Effects of Flibanserin on the Pharmacokinetics of a Combined Ethinylestradiol/Levonorgestrel Oral Contraceptive in Healthy Premenopausal Women: A Randomized Crossover Study.
Johnson-Agbakwu C; Brown L; Yuan J; Kissling R; Greenblatt DJ
Clin Ther; 2018 Jan; 40(1):64-73. PubMed ID: 29198449
[TBL] [Abstract][Full Text] [Related]
12. An investigation into the effect of tenidap sodium on the pharmacokinetics of a combined oral contraceptive.
Coates PE; Mesure R
Br J Clin Pharmacol; 1995; 39 Suppl 1(Suppl 1):47S-50S. PubMed ID: 7547095
[TBL] [Abstract][Full Text] [Related]
13. Pharmacokinetics of Oral Combination Contraceptive Drugs Containing Ethinyl Estradiol and Levonorgestrel in Healthy Female Chinese Volunteers.
Xin X; Wu Y; Liu X; Sun C; Geng T; Ding L
Drug Res (Stuttg); 2016 Feb; 66(2):100-6. PubMed ID: 26037079
[TBL] [Abstract][Full Text] [Related]
14. Pharmacokinetics of ethinylestradiol and levonorgestrel after administration of two oral contraceptive preparations.
Carol W; Klinger G; Jäger R; Kasch R; Brandstädt A
Exp Clin Endocrinol; 1992; 99(1):12-7. PubMed ID: 1628691
[TBL] [Abstract][Full Text] [Related]
15. Effect of pradigastat, a diacylglycerol acyltransferase 1 inhibitor, on the pharmacokinetics of a combination oral contraceptive in healthy female subjects.
Chen J; Bhansali S; Neelakantham S; Trusley C; Majumdar T; Rebello S; Sunkara G; Meyers C
Int J Clin Pharmacol Ther; 2015 Apr; 53(4):317-24. PubMed ID: 25740268
[TBL] [Abstract][Full Text] [Related]
16. Safety and tolerability of a new low-dose contraceptive patch in obese and nonobese women.
Kaunitz AM; Archer DF; Mishell DR; Foegh M
Am J Obstet Gynecol; 2015 Mar; 212(3):318.e1-8. PubMed ID: 25220709
[TBL] [Abstract][Full Text] [Related]
17. Correcting oral contraceptive pharmacokinetic alterations due to obesity: a randomized controlled trial.
Edelman AB; Cherala G; Munar MY; McInnis M; Stanczyk FZ; Jensen JT
Contraception; 2014 Nov; 90(5):550-6. PubMed ID: 25070547
[TBL] [Abstract][Full Text] [Related]
18. Pharmacokinetic interaction of solifenacin with an oral contraceptive containing ethinyl estradiol and levonorgestrel in healthy women: a double-blind, placebo-controlled study.
Taekema-Roelvink ME; Swart PJ; Kuipers ME; Krauwinkel WJ; Visser N; Smulders RA
Clin Ther; 2005 Sep; 27(9):1403-10. PubMed ID: 16291413
[TBL] [Abstract][Full Text] [Related]
19. No clinically relevant drug-drug interactions when dalcetrapib is co-administered with a monophasic oral contraceptive (Microgynon® 30).
Young A; Anzures-Cabrera J; Derks M
Int J Clin Pharmacol Ther; 2012 Apr; 50(4):248-56. PubMed ID: 22456295
[TBL] [Abstract][Full Text] [Related]
20. The effect of laquinimod, a novel immuno-modulator in development to treat Huntington disease, on the pharmacokinetics of ethinylestradiol and levonorgestrel in healthy young women.
Elgart A; Zur AA; Mimrod D; Dror V; Bar-Ilan O; Korver T; Spiegelstein O
Eur J Clin Pharmacol; 2019 Jan; 75(1):41-49. PubMed ID: 30191262
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
